Analysts Set Heartflow, Inc. (NASDAQ:HTFL) PT at $37.67

Shares of Heartflow, Inc. (NASDAQ:HTFL) have earned an average recommendation of “Moderate Buy” from the eight ratings firms that are presently covering the company, MarketBeat.com reports. One analyst has rated the stock with a sell recommendation, two have issued a hold recommendation and five have issued a buy recommendation on the company. The average 1-year price objective among brokers that have issued a report on the stock in the last year is $37.6667.

Several analysts have issued reports on HTFL shares. Wells Fargo & Company cut their target price on Heartflow from $38.00 to $35.00 and set an “overweight” rating for the company in a research note on Thursday, March 19th. JPMorgan Chase & Co. cut their target price on Heartflow from $40.00 to $35.00 and set an “overweight” rating for the company in a research note on Thursday, March 19th. Weiss Ratings reaffirmed a “sell (d)” rating on shares of Heartflow in a research note on Monday, December 29th. Finally, Canaccord Genuity Group boosted their price objective on Heartflow from $40.00 to $43.00 and gave the company a “buy” rating in a research report on Thursday, March 19th.

Heartflow Price Performance

Shares of HTFL opened at $31.34 on Wednesday. The firm has a market cap of $2.69 billion and a P/E ratio of -15.75. The stock has a 50 day simple moving average of $24.87 and a two-hundred day simple moving average of $29.54. Heartflow has a 1 year low of $20.13 and a 1 year high of $41.22.

Insider Buying and Selling

In other Heartflow news, insider Campbell Rogers sold 64,533 shares of the business’s stock in a transaction that occurred on Wednesday, April 1st. The stock was sold at an average price of $24.64, for a total value of $1,590,093.12. Following the completion of the sale, the insider owned 81,002 shares in the company, valued at approximately $1,995,889.28. The trade was a 44.34% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO John C.M. Farquhar sold 22,562 shares of the business’s stock in a transaction that occurred on Friday, April 10th. The shares were sold at an average price of $26.72, for a total value of $602,856.64. Following the completion of the sale, the chief executive officer owned 549,163 shares of the company’s stock, valued at $14,673,635.36. The trade was a 3.95% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders have sold 2,279,027 shares of company stock worth $63,146,573.

Institutional Trading of Heartflow

Several hedge funds and other institutional investors have recently bought and sold shares of HTFL. Wellington Management Group LLP bought a new stake in Heartflow in the third quarter valued at approximately $164,263,000. Baillie Gifford & Co. bought a new position in shares of Heartflow during the third quarter valued at approximately $101,182,000. Schusterman Interests LLC bought a new position in shares of Heartflow during the third quarter valued at approximately $65,274,000. Capricorn Investment Group LLC bought a new position in shares of Heartflow during the fourth quarter valued at approximately $48,178,000. Finally, Vanguard Group Inc. bought a new position in shares of Heartflow during the third quarter valued at approximately $48,871,000.

Heartflow Company Profile

HeartFlow, Inc (NASDAQ: HTFL) is a medical technology company that develops non-invasive diagnostic solutions for coronary artery disease. The company’s core offering translates coronary CT angiography (CTA) data into a patient-specific, three-dimensional physiological model of the coronary arteries. Using advanced image processing and computational modeling, HeartFlow’s analysis estimates fractional flow reserve (FFR) values throughout the coronary tree to identify ischemia-producing lesions without the need for invasive pressure-wire measurements.

HeartFlow’s cloud-based service integrates with clinical workflows: clinicians submit coronary CTA images and receive a detailed, color-coded 3D map and report that highlights lesion-specific FFR values and physiological impact.